ストックスクリーナーアプリを入手
12.49
1.11%
-0.14
前日終値:
$12.63
開ける：
$12.63
24時間の取引高:
1.19M
Relative Volume:
0.78
時価総額：
$1.26B
収益：
-
当期純損益:
$-44.84M
株価収益率:
-26.57
EPS:
-0.47
ネットキャッシュフロー:
$-44.23M
1週間 パフォーマンス:
+1.05%
1か月 パフォーマンス:
+22.45%
6か月 パフォーマンス:
-12.78%
1年 パフォーマンス:
+22.21%
1日の値動き範囲:
$12.21
$12.78
1週間の範囲:
$12.07
$13.22
52週間の値動き範囲:
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
12.49 | 1.26B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-10 | 開始されました | Oppenheimer | Outperform |
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - Simply Wall St
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance
Long Term Trading Analysis for (SPRY) - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN
Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor
ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa
neffy From ARS Pharmaceuticals, Inc - Pharmacy Times
ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - MSN
Decoding ARS Pharmaceuticals Inc (SPRY): A Strategic SWOT Insigh - GuruFocus.com
ARS Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks
Raymond James maintains $28 target on ARS Pharma stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals: Surging On Solid EarningsBut Real Challenges Await (NASDAQ:SPRY) - Seeking Alpha
Raymond James maintains $28 target on ARS Pharma stock - Investing.com India
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. - MSN
Earnings call transcript: ARS Pharmaceuticals Q4 2024 earnings beat expectations - Investing.com
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView
Sector Update: Health Care - TradingView
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings -March 20, 2025 at 07:45 am EDT - Marketscreener.com
ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Revenue $86.6M -March 20, 2025 at 07:13 am EDT - Marketscreener.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 EPS $0.48, vs. FactSet Est of $-0.04 Loss - Marketscreener.com
ARS Pharmaceuticals, Inc. SEC 10-K Report - TradingView
ARS Pharma Crushes Q4 with $49.9M Profit as Neffy Launch Gains Momentum - StockTitan
This company’s epinephrine nasal spray reverses allergic reactions—no needle required - Fast Company
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company
(SPRY) Investment Report - Stock Traders Daily
Steward Partners Investment Advisory LLC Raises Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday - Defense World
Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - Defense World
Scotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform Recommendation - Nasdaq
Rhumbline Advisers Buys 1,824 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ars pharmaceuticals director Laura Shawver sells $560,445 in stock By Investing.com - Investing.com Canada
US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients - Reuters
San Diego biotech gets FDA approval for EpiPen alternative for kids - MSN
Exploring High Growth Tech Stocks in the US Market - Simply Wall St
California biotech company gets FDA approval for EpiPen alternative for kids - East Bay Times
Scotiabank sets $30 target for ARS Pharmaceuticals stock - Investing.com
Scotiabank sets $30 target for ARS Pharmaceuticals stock By Investing.com - Investing.com Canada
FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients - Pharmaceutical Executive
FDA Approves Low-Dose Neffy Epinephrine Spray for Young Kids - Allergic Living
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment - Benzinga
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):